Group 1 - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions of dollars for shareholders [1] - The firm is investigating SpringWorks Therapeutics, Inc. regarding its proposed merger with Merck KGaA, where SpringWorks shareholders will receive $47.00 in cash per share [1] - The firm operates from the Empire State Building in New York City and has a successful track record in trial and appellate courts, including the U.S. Supreme Court [2][3] Group 2 - Monteverde & Associates PC emphasizes that no company, director, or officer is above the law and offers free information to shareholders with concerns [3] - The firm encourages potential clients to inquire about their litigation history and past recoveries for shareholders [4]

Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. related to its proposed acquisition by Merck KGaA, which is valued at approximately $3.4 billion [1]. Group 1 - The proposed acquisition will provide stockholders of SpringWorks Therapeutics with $47.00 for each share they hold [1]. - The transaction is expected to close in the second half of 2025 [1].

Market Overview - US stock index futures are all down before the market opens, with Dow futures down 0.06%, S&P 500 futures down 0.12%, and Nasdaq futures down 0.07% [1] - Major European indices show positive performance, with Germany's DAX up 0.52%, UK's FTSE 100 up 0.11%, France's CAC40 up 0.72%, and the Euro Stoxx 50 up 0.50% [2][3] - WTI crude oil is down 0.33% at $62.81 per barrel, while Brent crude oil is down 0.36% at $65.56 per barrel [3][4] Economic Data and Corporate Earnings - The upcoming week is significant for economic data and corporate earnings, with the April non-farm payroll report and Q1 inflation data being key focuses [5] - 180 S&P 500 companies are set to report quarterly earnings, with major companies like Apple, Amazon, Coca-Cola, Eli Lilly, Meta, Microsoft, and Chevron in the spotlight [5] Corporate Actions - Spirit AeroSystems has reached an agreement with Airbus for the acquisition of certain assets, with Boeing repurchasing its previously divested business for $4.7 billion in stock [8] - Merck has announced a $3.9 billion acquisition of SpringWorks Therapeutics to enhance its oncology drug portfolio, with the deal valued at approximately $3.4 billion in enterprise value [9] - Amazon has seen prices of nearly 1,000 products rise by an average of 30% due to the impact of tariffs, affecting various categories from electronics to clothing [10] Earnings Forecast - Upcoming earnings reports include companies such as NXP Semiconductors, AstraZeneca, BP, Novartis, Deutsche Bank, HSBC, Coca-Cola, Pfizer, UPS, General Motors, Daqo New Energy, and JinkoSolar [11]

Core Viewpoint - Merck has agreed to acquire SpringWorks Therapeutics for $3.9 billion in equity value to enhance its oncology drug business [1][2] Group 1: Acquisition Details - The acquisition price is set at $47 per share, translating to an equity value of approximately $3.9 billion and an enterprise value of about $3.4 billion (30 million euros) after accounting for SpringWorks' cash [1] - The transaction will be funded through available cash and new debt, and is expected to increase Merck's adjusted earnings per share by 2027 [1] Group 2: Strategic Implications - This acquisition marks one of Merck's largest pharmaceutical deals in recent years, reinforcing its ongoing efforts to build a cancer treatment portfolio [2] - Analysts suggest that this deal could accelerate Merck's growth, especially as sales of its cancer drug Bavencio slow down and its multiple sclerosis treatment Mavenclad faces patent expiration [2]

Core Viewpoint - Merck KGaA, Darmstadt, Germany is set to acquire SpringWorks Therapeutics for $47 per share, totaling an equity value of approximately $3.9 billion, which will enhance its Healthcare business and expand its presence in the U.S. market [1][2][9] Group 1: Acquisition Details - The acquisition price of $47 per share represents a 26% premium over SpringWorks' unaffected 20-day volume-weighted average price of $37.38 as of February 7, 2025 [1] - The enterprise value of the transaction is approximately $3.4 billion (€3.0 billion) based on SpringWorks' cash balance as of December 31, 2024 [1] - The transaction is expected to close in the second half of 2025, pending shareholder and regulatory approvals [9] Group 2: Strategic Importance - This acquisition aligns with Merck KGaA's strategy to diversify its portfolio and focus on rare tumors, which is a growing area in the healthcare sector [2][4] - The planned acquisition will immediately contribute to Merck KGaA's revenues and is expected to be accretive to earnings per share by 2027 [3] - Merck KGaA aims to leverage SpringWorks' innovative therapies to enhance its offerings in the rare tumor market [5][6] Group 3: SpringWorks' Portfolio - SpringWorks has developed first-in-class therapies for rare tumors, including OGSIVEO® for desmoid tumors and GOMEKLI™ for neurofibromatosis type 1-associated plexiform neurofibromas [7][8] - The acquisition will allow SpringWorks to expand its market reach beyond the U.S. and utilize Merck KGaA's global resources [6][11] - SpringWorks' ongoing pipeline includes additional programs targeting underserved tumor settings, which will complement Merck KGaA's existing portfolio [8][11]

Core Viewpoint - SpringWorks Therapeutics, Inc. anticipates a favorable opinion from the CHMP of the EMA regarding the marketing authorization application for nirogacestat in Q2 2025, aimed at treating adults with desmoid tumors [1] Company Overview - SpringWorks Therapeutics is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, with FDA-approved products including OGSIVEO (nirogacestat) for desmoid tumors and GOMEKLI™ (mirdametinib) for neurofibromatosis type 1 associated plexiform neurofibromas [2]

Company Overview - SpringWorks Therapeutics (SWTX) shares increased by 9% to close at $44.93, following a notable trading volume that exceeded typical levels, contrasting with an 11.3% loss over the past four weeks [1] - The rise in stock price is linked to growing investor optimism regarding the company's lead product, Ogsiveo (nirogacestat), which is approved for treating Desmoid tumors and has seen rapid uptake since its late 2023 approval [2] Financial Performance - The company is expected to report a quarterly loss of $0.79 per share, reflecting a year-over-year increase of 33.1%, while revenues are projected to be $64.19 million, marking a 205.5% increase from the same quarter last year [3] - The consensus EPS estimate for SpringWorks has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - SpringWorks Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Pharming Group N.V. Sponsored ADR (PHAR), saw a 3.8% increase in its stock price, closing at $8.58, despite a -5.8% return over the past month [4] - Pharming Group's consensus EPS estimate for the upcoming report has also remained unchanged at -$0.25, representing a 31.6% decline from the previous year [5]

Core Viewpoint - SpringWorks Therapeutics reported a wider loss per share in Q4 2024 compared to estimates, despite a significant increase in total revenues driven by the successful launch of its product Ogsiveo [1][2][6]. Financial Performance - The company incurred a loss of $1.04 per share in Q4 2024, exceeding the Zacks Consensus Estimate of a loss of 72 cents, and improved from a loss of $1.44 per share in the same quarter last year [1]. - Total revenues for Q4 2024 reached $61.5 million, surpassing the Zacks Consensus Estimate of $60 million, and significantly up from $5.4 million in the year-ago quarter [2]. - For the full year 2024, SpringWorks generated revenues of $191.6 million, compared to $5.4 million in the previous year, with a loss of $3.48 per share, an improvement from a loss of $5.15 per share in the prior year [6]. Product Development and Market Position - Ogsiveo became the first approved product in SpringWorks' portfolio and the first drug approved for treating desmoid tumors, with net product revenues increasing nearly 24.7% sequentially in Q4 due to strong demand [2][3]. - The FDA approved Ogsiveo in November 2023 for adult patients with progressing desmoid tumors, and the company aims to establish it as the standard of care [2][4]. - The marketing authorization application for Ogsiveo is under review with the European Medicines Agency (EMA), with potential approval expected in 2025 [7]. Research and Development - Research and development expenses in Q4 totaled $60.2 million, a 37.7% increase from the previous year, attributed to higher drug manufacturing costs and ongoing clinical studies [4]. - Selling, general, and administrative expenses reached $77.1 million, up approximately 28.9% year-over-year, primarily due to costs associated with the launch of Gomekli [5]. Stock Performance - Following the earnings announcement, SpringWorks shares rose by 7.5% on February 20, and the stock has increased by 22.1% over the past year, contrasting with an 8.3% decline in the industry [3].

YANCOAL AUSTRALIA LTD | ADDRESS: | Level 18, Tower 2, 201 Sussex Street, | | --- | --- | | | Sydney NSW 2000 | | PHONE: | 61 2 8583 5300 | | FAX: | 61 2 8583 5399 | | WEBSITE: | www.yancoal.com.au | 20 February 2025 ASX Release: 2024 Financial Results Presentation Authorised for lodgement by the Board of Yancoal Australia Investor Relations Contact: Brendan Fitzpatrick, GM Investor Relations Email: Brendan.Fitzpatrick@yancoal.com.au Additional information about the company can be found at www.yancoal.com.au ...

Company Performance - SpringWorks Therapeutics reported a quarterly loss of $1.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.72, representing an earnings surprise of -44.44% [1] - The company posted revenues of $61.55 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 2.52%, and showing significant growth from $5.45 million in the same quarter last year [2] - Over the last four quarters, SpringWorks has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - SpringWorks Therapeutics shares have increased approximately 54.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 4.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.73 on revenues of $64.18 million, and for the current fiscal year, it is -$2.05 on revenues of $332.27 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which SpringWorks belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]